Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

285
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
285
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

308
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
308
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

279
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
279
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

489
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Utility of Cell-Free DNA Hydroxymethylation Profiling in Small-Cell Lung Cancer.

International journal of molecular sciences·2026
Same author

Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications.

Current oncology (Toronto, Ont.)·2024
Same author

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).

Current oncology (Toronto, Ont.)·2023
Same author

A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment.

Current hematologic malignancy reports·2023
Same author

Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis.

Rare tumors·2022
Same author

Empathy.

Journal of patient experience·2021

Related Experiment Video

Updated: Nov 11, 2025

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.3K

The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development.

Danielle Benedict Sacdalan1,2, Josephine Anne Lucero3

  • 1Department of Pharmacology and Toxicology, University of the Philippines Manila College of Medicine, Manila, Philippines.

Oncotargets and Therapy
|March 29, 2021
PubMed
Summary

Cancer

Keywords:
biomarkersimmune checkpoint inhibitorimmunosuppressioninflammationtumorigenesis

More Related Videos

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.5K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Related Experiment Videos

Last Updated: Nov 11, 2025

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.3K
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.5K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Area of Science:

  • Oncology and Immunology

Background:

  • Cancer's evasion of immune destruction is a key characteristic.
  • Chronic inflammation promotes immune escape and tumor development.
  • The tumor microenvironment can hinder anti-cancer treatments.

Purpose of the Study:

  • To review the relationship between inflammation and immunosuppression in cancer.
  • To examine their impact on the tumor microenvironment.
  • To discuss implications for immune checkpoint inhibitor therapy and biomarkers.

Main Methods:

  • Literature review of inflammation, immunosuppression, and cancer.
  • Analysis of tumor microenvironment dynamics.
  • Exploration of immune checkpoint inhibitor mechanisms and biomarkers.

Main Results:

  • Inflammation and immunosuppression create a tumor microenvironment that supports cancer growth.
  • These processes can reduce the effectiveness of immune checkpoint inhibitors.
  • Predictive biomarkers are crucial for optimizing therapy.

Conclusions:

  • Understanding the interplay of inflammation and immunosuppression is vital for cancer treatment.
  • Targeting these pathways may enhance anti-tumor immunity.
  • Biomarker development is essential for personalized immune checkpoint inhibitor therapy.